Teva Pharmaceutical Industries (TEVA) Equity Ratio: 2009-2024
Historic Equity Ratio for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to 0.14.
- Teva Pharmaceutical Industries' Equity Ratio rose 19.07% to 0.18 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.18, marking a year-over-year increase of 19.07%. This contributed to the annual value of 0.14 for FY2024, which is 26.80% down from last year.
- Teva Pharmaceutical Industries' Equity Ratio amounted to 0.14 in FY2024, which was down 26.80% from 0.19 recorded in FY2023.
- In the past 5 years, Teva Pharmaceutical Industries' Equity Ratio registered a high of 0.24 during FY2021, and its lowest value of 0.14 during FY2024.
- For the 3-year period, Teva Pharmaceutical Industries' Equity Ratio averaged around 0.17, with its median value being 0.19 (2023).
- Its Equity Ratio has fluctuated over the past 5 years, first increased by 8.00% in 2021, then decreased by 26.80% in 2024.
- Over the past 5 years, Teva Pharmaceutical Industries' Equity Ratio (MRY) stood at 0.22 in 2020, then grew by 8.00% to 0.24 in 2021, then dropped by 17.18% to 0.20 in 2022, then dropped by 4.33% to 0.19 in 2023, then fell by 26.80% to 0.14 in 2024.
- Its Equity Ratio stands at 0.14 for FY2024, versus 0.19 for FY2023 and 0.20 for FY2022.